GL1X · GenesisL1 explorer

MolNFT v1 · #110017 · protein

Human CD38 complexed with inhibitor 1 [6-fluoro-2-methyl-4-[(2,3,6- TRICHLOROBENZYL)AMINO]QUINOLINE-8-carboxamide]

4XJS · ADP-ribosyl CYCLASE/CYCLIC ADP-ribose hydrolase 1: “Human CD38 complexed with inhibitor 1 [6-fluoro-2-methyl-4-[(2,3,6…”. X-ray diffraction, 2 ligands (733, HSX), 3 pockets (best druggability 0.55). MolNFT v1 #110017 on GenesisL1…

PDB
4XJS
Type
protein
Length
239 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
ADP-ribosyl CYCLASE/CYCLIC ADP-ribose hydrolase 1
EC
3.2.2.6, 2.4.99.20
UniProt
P28907
Ligands
733, HSX
Pockets
3 · best druggability 0.55

Structure

x-ray diffraction · 1 distinct chain · 45% helix, 15% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AADP-ribosyl CYCLASE/CYCLIC ADP-ribose hydrolase 1 (EC 3.2.2.6, 2.4.99.20)protein23945% helix, 15% strandP28907

Ligands and binding sites

  • 733 · 6-fluoro-2-methyl-4-[(2,3,6-trichlorobenzyl)amino]quinoline-8-carboxamide · ligand · chains A
  • HSX · 5-O-phosphono-alpha-D-ribofuranose · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12780.550.7640733, HSX
2540.520.8819empty
3650.280.7316empty

Modifications

Observed in the structure: 5 disulfide, 1 covalent (disulfide, covalent ligand).

Compared structures

  • 4XJS · Human CD38 complexed with inhibitor 1 [6-fluoro-2-methyl-4-[(2,3,6-trichlorobenzyl)amino]q… · the same entry in another collection · chain A against A, TM-score 1.00
  • P28907 · AlphaFold monomer V2.0 prediction for ADP-ribosyl CYCLASE/CYCLIC ADP- ribose hydrolase 1… · a predicted model of the same protein · chain A against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.